Science & Health
The argument arrives reliably whenever a country moves to regulate cannabis: roads will become more dangerous. It is a compelling claim, and a politically effective one. But the evidence underpinning it is considerably more ambiguous than the campaigns that deploy it tend to admit.
Recent coverage in The Boston Globe examined how anti-legalisation groups in the United States have framed driving safety as a core argument against cannabis reform — and found that the underlying science is, in the Globe's own words, "very unclear." That ambiguity matters well beyond North America. As European countries from Germany to Luxembourg move along regulatory paths of their own, and as Malta's adult-use framework under Chapter 628 of the Laws of Malta enters its fourth year of operation, the question of cannabis and road safety belongs squarely in the European policy conversation.
What Research Actually Shows
There is no serious scientific dispute that THC — cannabis's primary psychoactive compound — can impair certain driving-relevant skills. Reaction time, divided attention, and lane-tracking performance can all be affected, particularly in the hours immediately following consumption. That much is established.
What is far less settled is how that laboratory impairment translates into real-world crash risk. Studies examining actual traffic data have produced inconsistent findings. Some show a modest increase in crash likelihood among drivers who test positive for THC; others find little or no statistically significant effect once confounding variables — age, alcohol co-use, time of day, and pre-existing driving behaviour — are controlled for. A further complication: THC metabolites can remain detectable in blood or urine for days or weeks after any psychoactive effect has passed, meaning a positive test does not reliably indicate recent or impairing consumption.
This is not a minor methodological footnote. It sits at the centre of every policy debate about roadside drug testing, and it is one reason why the science resists the clean narrative that advocacy campaigns on either side prefer.
The Measurement Problem
Alcohol impairment law is built on a relatively stable scientific foundation: blood alcohol concentration correlates reasonably well with impairment across a population, and legal limits — 0.5 g/L in Malta and most of the EU — emerged from decades of crash data. No equivalent threshold exists for THC. The compound behaves differently depending on frequency of use, individual metabolism, body composition, and the specific cannabis consumed. A person who uses cannabis regularly may show high blood THC levels with little functional impairment; an occasional consumer may show lower levels with greater effect.
Researchers continue to develop tools — cognitive performance tests, driving simulators, oral fluid assays — that might one day offer something closer to an impairment standard rather than a detection standard. But that science is not yet mature enough to anchor legislation confidently.
What This Means for Malta and Europe
Malta's ARUC (Authority on the Responsible Use of Cannabis), the regulator overseeing the island's adult-use cannabis framework, has not publicly proposed specific per se THC driving limits, and Maltese road safety law continues to operate under general impaired driving provisions rather than cannabis-specific blood thresholds. That approach is, arguably, more scientifically defensible than arbitrary numerical limits — provided enforcement is consistent and well-resourced.
Across the EU, member states vary considerably in their approach. Some apply zero-tolerance THC policies for drivers; others rely on officer-assessed impairment. The European Union Drugs Agency (EUDA), the bloc's drug monitoring body, has flagged the lack of harmonised standards as a gap in both data collection and enforcement policy — making cross-border comparisons extremely difficult to interpret.
For Cannabis Harm Reduction Associations (CHRAs) — the member-based clubs through which adults in Malta legally access cannabis — the driving question has practical implications. Responsible consumption guidance, including clear messaging about not driving after use, forms part of the harm-reduction mandate these associations carry. Some CHRAs in Malta have incorporated such guidance into member-facing materials, though the specifics vary.
When the Science Is Unclear, Humility Is the Policy
The honest position — the one the research actually supports — is this: cannabis can impair driving under some conditions for some consumers, the degree of risk depends on factors that roadside tests currently cannot reliably measure, and the population-level effect of cannabis regulation on road safety remains genuinely uncertain. Some studies from jurisdictions that regulated early suggest no statistically significant increase in traffic fatalities; others find modest increases in specific demographic groups. The picture is not clean.
That uncertainty does not argue for dismissing road safety concerns — it argues for investing in better measurement tools, funding longitudinal traffic studies in newly regulated markets, and resisting the temptation to draft policy around a crisis that the data has not yet confirmed.
Anti-cannabis campaigns that present the driving risk as settled science are overstating what we know. But so would anyone who argued the risk is zero. What the research actually demands is something rarer than either position: epistemic patience — and the political willingness to say "we are still learning." For Malta and its European neighbours, building that nuance into regulatory frameworks now will matter more than any slogan, in either direction, suggests. As our guide to Malta cannabis law outlines, the local framework is still evolving — and how it handles road safety messaging will be one of the clearest tests of whether evidence, rather than politics, is driving the wheel.
Sources:
The Boston Globe
Featured image: Photo by Irina Iriser on Pexels
Members Discussion